Results 231 to 240 of about 4,824,048 (369)
This study identifies alnustone, a natural compound from Alpinia katsumadai, as a potent therapeutic agent for MASLD and MASH. Alnustone enhances mitochondrial fatty acid β‐oxidation by directly targeting calmodulin, improving liver steatosis, fibrosis, and insulin resistance in vivo.
Shourui Hu+13 more
wiley +1 more source
Is There Evidence That Oral Hypoglycemic Agents Reduce Cardiovascular Morbidity or Mortality? No [PDF]
Sameer Kassem, Itamar Raz
openalex +1 more source
Cardiovascular risk management beyond statins: review of new therapies available in Italy. [PDF]
Capuozzo M+4 more
europepmc +1 more source
In the context of chronic hyperglycemia, a DDR is initiated, leading to the pathological activation of DNA‐PKcs in the diabetic heart. This activated DNA‐PKcs directly interacts with and phosphorylates YAP1 at Thr226, thereby increasing the nuclear expression of YAP1.
Junyan Wang+10 more
wiley +1 more source
Prescribing Patterns of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Patients With T2DM and ASCVD in South Korea. [PDF]
Eom YR, Joo H, Chae SE, Je NK.
europepmc +1 more source
This study demonstrates that the transport of lactate to the mitochondria is of critical importance in determining the functions of macrophages by altering mitochondrial respiration. In macrophages, this lactate transport mechanism regulates glucose homeostasis by influencing the functions of insulin‐secreting cells in the pancreatic islets.
Lingling Chen+9 more
wiley +1 more source
Development of a Synthetic Drug Information Database for Cardiovascular Agents
Yuta Kasahara+7 more
openalex +2 more sources
Effects of gadolinium contrast agent on aortic blood flow and myocardial strain measurements by phase-contrast cardiovascular magnetic resonance [PDF]
Erik Hedström+4 more
openalex +1 more source
Management of dyslipidaemia in patients with comorbidities-facing the challenge: type 1 diabetes mellitus. [PDF]
Kaser S+5 more
europepmc +1 more source